Table
From: Experience with pediatric sarcoidosis at a centre in Mumbai, India
Cohort features | Characteristics at Onset/ 1st visit | Follow-up ( ≥ 1 year) |
|---|---|---|
Number(N) Median age (years) [IQR] | 12 Onset:1.25[0.9-1.7]Diagnosis:7.8[4.9-9.9] | 8 |
Fever; median duration | 10/12(83.3%);18 months | Resolution |
Arthritis | 7/12(58.3%) | Resolution |
Skin manifestations | 7/12(58.3%) | Resolved 6/8(75%) |
Ocular abnormalities | Onset: 6/12(50%), 1st visit: 5/6(83.3%) | 2/5(40%) |
Triad-Arthritis,Rash,Uveitis | Onset: 5/12(41.7%), 1st visit: 3/5(60%) | None |
Systemic features | Sicca(1),Adenopathy(4),GIT(4), Pulmonary(5), Organomegaly(9) | Aortoarteritis(1/8) Interstitial lung(1/8) |
Growth retardation | 12/12(100%) | 5/8(62.5%) |
Median Steroid dose(mg/kg/day) [IQR] Median Methotrexate dose(mg/m2BSA) [IQR] Others: | 0.6[0.2-0.8] 10.1[0-10.4] | 0.3[0.1-0.3] 10.9[9.7-15.3] Azathioprine(vasculitic rash)(1),Mycophenolate(uveitis)(1) |
Treatment side-effects | - | Hepatotoxicity(1/8) Osteoporosis(2/8) Cataracts(3/8) |